Omnicell, Inc. · NASDAQ:OMCL
Omnicell — Investor Presentation (January 2021)
21 slides from Omnicell's investor presentation, Jan 13, 2021
Slide 1: Investor Update January 13, 2021
Investor Update January 13, 2021
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains “forward-looking statements” within the meaning of federal securities laws. These forward-looking statements include statements with respect to guidance, estimated full-year 2020 financial and operating results, 2025 targets, growth expectations
Slide 3: Vision: The Autonomous Pharmacy
Vision The Autonomous Pharmacy will transform the pharmacy care delivery model by enabling the provider to practice at the top of their license
Slide 4: FY 2020 Preliminary Update & Outperformance
FY 2020 Preliminary Update & Outperformance Key Metric Prior Guidance Update Projected Long-Term Value Upside ✔Clear leadership position in the digital transformation of healthcare with $70B+ TAM Product Bookings$865-$900M Total Revenue$881-$887M Non-GAAP EBITDA-Non-GAAP EPS$2.35-$2.40/share ~$1B $8
Slide 5: Investment highlights: category creator transforming pharmacy care delivery
1Category creator positioned to transform the pharmacy care delivery model 2Leading strategic partner to health systems in large and growing market segments 3Resilient, high-visibility revenue accelerated by high-growth SaaS, Subscription Software & Tech-Enabled Services 4Demonstrated track record o
Slide 6: Expensive and Error-Prone Medication Management Reality
1Omnicell Provides Solutions for an Expensive and Error-Prone Medication Management Reality 6 Deliver Results Safety 25,000 Errors Annually in Hospitals1 4 Errors Per Day in Outpatient Pharmacies2 47 million Doses Lost to Drug Diversion4 1 Error Per 200 Drug Dispenses1,5 Enhanced Patient Safety 99.9
Slide 7: Autonomous Pharmacy Framework
1Autonomous Pharmacy Framework Increasing healthcare value In 2019, leading health systems jointly created a framework analyzing the technological maturity of pharmacies The group determined there was a significant opportunity to drive greater healthcare value The group established a 5-level framewo
Slide 8: Omnicell's Autonomous Pharmacy is a New Category of Solutions
1Omnicell’s Autonomous Pharmacy is a New Category of Solutions That Fundamentally Improve Provider Outcomes Omnicell OneCPDSIV RIISEnlivenHealth Omnicell340B Future Services1 One Platform Omnicell Connected Devices XT Automated Dispensing Systems Anesthesia Workstation XR2 Robot IV Robot IVX Workflo
Slide 9: Unparalleled Breadth and Depth of Customer Base
2Omnicell Has Unparalleled Breadth and Depth of Customer Base That Enables Significant Ability to Bring New Innovations to Market 145 sole source contracts with top 300 US health systems1 ~50% install base in US hospitals1 17 of top 20 US News Honor Roll hospitals1 45%Omnicell has over 25 years >60%
Slide 10: Leader in Large and Growing Segments
2Leader in Large and Growing Segments Omnicell is growing its leadership position across a $70B+ total addressable market Estimated Total Addressable Market Opportunity1 Key Advanced Services Point of Care$20B Central Pharmacy$15B $12B Omnicell One Omnicell340B CPDS IV RIIS $23B and PayersEnlivenHea
Slide 11: Robust Backlog and Deep Customer Relationships
Robust BacklogRobust product backlog Connected Devices, Software Licenses & Other4 Recurring Technical Services and Other Recurring6 Recurring SaaS, Subscription Software & Tech-Enabled Services5 Deep Customer Relationships Customer Retention 145 of the top 300 U.S. health systems in long-term, sole
Slide 12: SaaS, Subscription Software & Tech-Enabled Services
SaaS, Subscription Software & Tech-Enabled Services (% of Total Revenue) 20-30% 9-10% ~6% ✔ Leveraging established channel and strong customer relationships ✔ Strong demand driven by increasing provider digitization and need to evolve medication supply chain ✔ Omnicell’s cloud-based services enable
Slide 13: Driving Profitable Growth Through Disciplined Execution
4Driving Profitable Growth Through Disciplined Execution Expected Annual Revenue ($ in Millions) $1,900-$2,000 $1,650-$1,750 $1,085-$1,105 Execute value-enhancing M&A Drive innovation and continue to deliver the Autonomous Pharmacy Vision Continue market share gains Capitalize on upgrade cycles 2021
Slide 14: Targeted Non-GAAP Operating and EBITDA Margins
Targeted Non-GAAP Operating Margin (%) ~21% ~17% Key Drivers of Margin Enhancement ✔ Improving Business Mix – SaaS, Subscription Software & Tech-Enabled Services targeted to represent 20-30% of revenue by 2025, supporting strong gross margins ~13% 2020E ~18% 2020E 2021E Targeted Non-GAAP EBITDA Marg
Slide 15: Omnicell's Total Shareholder Return
Omnicell’s Total Shareholder Return Time Period Omnicell (OMCL) S&P Healthcare (XLV) Outperformance 1 Year +47% +13% +34% 3 Year +147% +45% +102% 5 Year +286% +72% +214% 10 Year +731% +328% +402% Omnicell outperformed the S&P Healthcare Index on all timeframes NOTE: Total shareholder returns are bas
Slide 16: Investment highlights summary
1Category creator positioned to transform the pharmacy care delivery model Large portion of the healthcare sector: $1,250B annually globally 2Leading strategic partner to health systems in large and growing market segments Clear leadership position in the digital transformation of healthcare with $7
Slide 17: Environment, Social, Governance
ENVIRONMENT: INNOVATING FOR ENERGY EFFICIENCY SOCIAL: EVERY VOICE COUNTS GOVERNANCE: ACTING WITH INTEGRITY We design our products to be energy efficient Currently working with the EPA to receive Energy Star certification for our products Headquarters is LEED Gold certified and includes a 151 kW sola
Slide 18: Omnicell platform: services, connected devices, outcomes
Service Intelligence Technical Services Professional Services Omnicell One Advisory Services Outcomes Safety + Omnicell 340B Support 340B Analysis Inventory Analytics Contract Pharmacy Diversion Management Compliance EnlivenHealth Financial Savings + Efficiency Automation / 340B Split BillingInvento
Slide 19: Reconciliation of GAAP to non-GAAP income from operations and net income
Reconciliation of GAAP income from operations to non-GAAP income from operations: GAAP income from operations$ 31,600-34,600 GAAP operating income % to total revenues3.5%-3.9% Share-based compensation expense~44,700 Amortization of acquired intangibles~19,600 Acquisition-related expenses~5,600 Sever
Slide 20: Reconciliation of GAAP to non-GAAP EPS and EBITDA
Reconciliation of GAAP net income per share - diluted to non-GAAP net income per share - diluted: Shares - diluted GAAP43,743 Shares - diluted Non-GAAP43,743 GAAP net income per share - diluted$ 0.65-0.70 Share-based compensation expense~1.02 Amortization of acquired intangibles~0.45 Acquisition-rel
Slide 21: Omnicell
ro) Omnicell